Soligenix Inc (SNGX) Stock Price, Quote & News

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology th...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 538 8200

Fax: 609 452 6467

Website: www.soligenix.com

Address:

29 Emmons Drive, Suite B-10, Princeton, United States

splendor Aug. 4 at 6:32 PM

$QUCY and $SNGX is my 2 favourite Potential to ge a big funding 1000%+ Do your resarch please.

0 · Reply

BmoreBoy89 Aug. 4 at 2:25 PM

$SNGX The question I have is the potential R/S based on being rejected by CEPI, or an anticipation of a delayed response?

4 · Reply

durocali Aug. 4 at 1:31 PM

$SNGX incoming 20-1 reverse split: https://files.quartr.com/reports/ac0c5f4045bf2e9333006e4b39d6cf21-2026-08-03-20-07-04.pdf?ref=U0E=

1 · Reply

splendor Jul. 31 at 3:55 PM

$SNGX 👀 Come back to 1$ + before the news. When the funding cepi news will coming 6$ is my first target

1 · Reply

splendor Jul. 31 at 1:48 PM

$SNGX Called this two weeks ago: as expected, high-probability Ebola vaccine funding news landed this past week with CEPI announcing its first award under the open call ($8.5M to Hilleman Laboratories). This is just the first step. With significant capital still remaining in the funding pool, expect additional awards for other key players in the coming days.

2 · Reply

fda_tracker Jul. 29 at 8:05 PM

$SNGX Phase 3 trial w/est Jul completion date NCT06470451: https://www.clinicaltrials.gov/study/NCT06470451 Trial Tracker: https://www.fdatracker.com/trial-tracker/

1 · Reply

Axielg Jul. 29 at 12:40 PM

$SNGX anyone know how much longer it will be to get a funding decision?

1 · Reply

BmoreBoy89 Jul. 27 at 2:22 PM

$SNGX $DCOY SNGX is next.

1 · Reply

NoQinyoface Jul. 24 at 6:54 PM

$SNGX PUSh

0 · Reply

PattyBergeron Jul. 23 at 5:37 PM

$SNGX https://www.bbc.com/news/articles/cpwep8xnkrqo

1 · Reply

Soligenix Proxy statement: Proxy filing

Aug 3, 2026, 8:00 AM EDT - 1 day ago

Soligenix Proxy statement: Proxy filing

Jul 23, 2026, 8:00 AM EDT - 12 days ago

Soligenix Proxy statement: Proxy filing

Jul 21, 2026, 8:00 AM EDT - 14 days ago

Soligenix Proxy statement: Proxy filing

2026-06-08T11:45:52.000Z - 2 months ago

Soligenix to apply for vaccine development funding for Bundibugyo Ebola vaccine

Jun 8, 2026, 7:30 AM EDT - 2 months ago

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

May 26, 2026, 7:30 AM EDT - 2 months ago

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

2026-05-08T12:43:19.000Z - 3 months ago

Soligenix reports Q1 EPS (28c) vs. (97c) last year

May 8, 2026, 7:30 AM EDT - 3 months ago

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026, 7:00 AM EDT - 3 months ago

Soligenix Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 3 months ago

Soligenix Earnings release: Q1 2026

2026-05-04T11:16:01.000Z - 3 months ago

Soligenix price target lowered to $1.50 from $10 at Alliance Global

2026-04-28T12:08:02.000Z - 3 months ago

Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma

Apr 28, 2026, 7:30 AM EDT - 3 months ago

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Apr 8, 2026, 7:00 AM EDT - 4 months ago

Soligenix Slides: Corporate presentation

2026-04-02T12:03:59.000Z - 4 months ago

Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial

Apr 2, 2026, 7:30 AM EDT - 4 months ago

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Mar 31, 2026, 7:30 AM EDT - 4 months ago

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Mar 31, 2026, 7:00 AM EDT - 4 months ago

Soligenix Annual report: Q4 2025

2026-03-26T11:36:24.000Z - 4 months ago

Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease

Mar 26, 2026, 7:30 AM EDT - 4 months ago

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Mar 26, 2026, 7:00 AM EDT - 4 months ago

Soligenix Slides: Corporate presentation

Mar 23, 2026, 7:30 AM EDT - 4 months ago

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

Mar 19, 2026, 8:00 AM EDT - 4 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.

2026-03-19T11:36:43.000Z - 4 months ago

Soligenix announces HyBryte clinical summary published

Mar 19, 2026, 7:30 AM EDT - 4 months ago

Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

Mar 17, 2026, 7:00 AM EDT - 5 months ago

Soligenix Slides: Corporate presentation

2026-03-10T11:42:32.000Z - 5 months ago

Soligenix says SGX945 granted PIM designation in UK by MHRA

Mar 10, 2026, 7:30 AM EDT - 5 months ago

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

2026-02-26T13:00:59.000Z - 5 months ago

Soligenix receives positive opinion from EMA for OOD request for dusquetide

Feb 26, 2026, 7:30 AM EST - 5 months ago

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Feb 24, 2026, 7:30 AM EST - 5 months ago

Soligenix to Present at BIO Investment & Growth Summit

Feb 12, 2026, 7:30 AM EST - 6 months ago

Soligenix Details Recent Progress and Upcoming Milestones

2025-12-18T12:41:21.000Z - 8 months ago

Soligenix’s SGX945 in Behcet’s Disease published in Rheumatology (Oxford)

Dec 18, 2025, 7:30 AM EST - 8 months ago

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

2025-12-17T12:36:34.000Z - 8 months ago

Soligenix announces results from Phase 2a trial of SGX302

Dec 17, 2025, 7:30 AM EST - 8 months ago

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Dec 3, 2025, 8:30 AM EST - 8 months ago

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

2025-11-19T12:35:43.000Z - 9 months ago

Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte

Nov 19, 2025, 7:30 AM EST - 9 months ago

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Nov 7, 2025, 7:30 AM EST - 9 months ago

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Nov 7, 2025, 7:00 AM EST - 9 months ago

Soligenix Quarterly report: Q3 2025

Oct 14, 2025, 7:30 AM EDT - 10 months ago

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

2025-10-07T11:35:32.000Z - 10 months ago

Soligenix’s HyBryte achieves safety milestone in Phase 3 T-cell lymphoma trial

Oct 7, 2025, 7:30 AM EDT - 10 months ago

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

2025-09-30T11:35:29.000Z - 11 months ago

Soligenix expands European Medical Advisory Board for CTCL

Sep 30, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Sep 29, 2025, 4:05 PM EDT - 11 months ago

Soligenix Announces Closing of $7.5 Million Public Offering

Sep 26, 2025, 6:33 AM EDT - 11 months ago

Soligenix Announces Pricing of $7.5 Million Public Offering

Sep 23, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

2025-09-19T21:05:11.000Z - 11 months ago

Soligenix files to sell 2.91M shares of common stock, 2.91M warrants

Sep 19, 2025, 8:00 AM EDT - 11 months ago

Soligenix Registration statement: Registration Filing

Sep 19, 2025, 7:00 AM EDT - 11 months ago

Soligenix Slides: Corporate Presentation

2025-09-04T11:35:46.000Z - 11 months ago

Soligenix’s ThermoVax platform shows efficacy in vaccine stability

Sep 4, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Sep 2, 2025, 7:30 AM EDT - 1 year ago

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-18T11:35:27.000Z - 1 year ago

Soligenix’s dusquetide granted Orphan Drug Designation in Behcet’s Disease

Aug 18, 2025, 7:30 AM EDT - 1 year ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Soligenix Quarterly report: Q2 2025

Aug 14, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

2025-08-13T22:00:32.000Z - 1 year ago

Soligenix receives FDA orphan designation for dusquetide

Aug 8, 2025, 8:30 AM EDT - 1 year ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Jul 8, 2025, 7:30 AM EDT - 1 year ago

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 1, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jun 6, 2025, 9:37 AM EDT - 1 year ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

May 9, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

May 8, 2025, 7:00 PM EDT - 1 year ago

Soligenix Quarterly report: Q1 2025

May 8, 2025, 7:00 PM EDT - 1 year ago

Soligenix Earnings release: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Soligenix Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Soligenix Proxy statement: Proxy Filing

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Mar 25, 2025, 8:30 AM EDT - 1 year ago

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 21, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Soligenix Annual report: Q4 2024

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Soligenix Earnings release: Q4 2024

Mar 6, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Feb 4, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at BIO CEO & Investor Conference

Jan 16, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at Upcoming Investor Conferences

Jan 14, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 1 year ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 2, 2024, 7:30 AM EST - 1 year ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Nov 19, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 15, 2024, 7:30 AM EST - 1 year ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 14, 2024, 7:15 AM EST - 1 year ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 8, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Nov 7, 2024, 7:00 PM EST - 1 year ago

Soligenix Quarterly report: Q3 2024

Nov 7, 2024, 7:00 PM EST - 1 year ago

Soligenix Earnings release: Q3 2024

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

splendor Aug. 4 at 6:32 PM

$QUCY and $SNGX is my 2 favourite Potential to ge a big funding 1000%+ Do your resarch please.

0 · Reply

BmoreBoy89 Aug. 4 at 2:25 PM

$SNGX The question I have is the potential R/S based on being rejected by CEPI, or an anticipation of a delayed response?

4 · Reply

durocali Aug. 4 at 1:31 PM

$SNGX incoming 20-1 reverse split: https://files.quartr.com/reports/ac0c5f4045bf2e9333006e4b39d6cf21-2026-08-03-20-07-04.pdf?ref=U0E=

1 · Reply

splendor Jul. 31 at 3:55 PM

$SNGX 👀 Come back to 1$ + before the news. When the funding cepi news will coming 6$ is my first target

1 · Reply

splendor Jul. 31 at 1:48 PM

2 · Reply

fda_tracker Jul. 29 at 8:05 PM

$SNGX Phase 3 trial w/est Jul completion date NCT06470451: https://www.clinicaltrials.gov/study/NCT06470451 Trial Tracker: https://www.fdatracker.com/trial-tracker/

1 · Reply

Axielg Jul. 29 at 12:40 PM

$SNGX anyone know how much longer it will be to get a funding decision?

1 · Reply

BmoreBoy89 Jul. 27 at 2:22 PM

$SNGX $DCOY SNGX is next.

1 · Reply

NoQinyoface Jul. 24 at 6:54 PM

$SNGX PUSh

0 · Reply

PattyBergeron Jul. 23 at 5:37 PM

$SNGX https://www.bbc.com/news/articles/cpwep8xnkrqo

1 · Reply

JK1033 Jul. 23 at 1:32 PM

$SNGX Ride or die, good or bad, in this to the end.

0 · Reply

splendor Jul. 23 at 5:48 AM

$SNGX Ebola death toll surpasses 1,000 in DR Congo, Uganda

1 · Reply

GreedyGopher Jul. 22 at 2:55 PM

$SNGX This turd is not worth 5 cents....

1 · Reply

GreedyGopher Jul. 22 at 2:11 PM

$SNGX Not to say I TOLD YOU SO...but really, another reverse split followed by mass dilution? They have already reduced long term investores shares to 1/225th over the last 4 years, now they are going to do it again? and then follow that with massive dilution?? Where is the SEC or NASDAQ to step in and say enough is enough? They have stolen their investors money for years, not brought ANYTHING to market, and Schaber continues to take a huge salary and grow his wealth.... DELIST this turd now!!

4 · Reply

Jmiz1986 Jul. 21 at 8:56 PM

$SNGX we have till sept 17 for something to happen before they vote for a R/S and more dilution. Let’s hope we hear something before hand. 2 months is a lot if time https://www.stocktitan.net/sec-filings/SNGX/pre-14a-soligenix-inc-preliminary-proxy-statement-436de0b0b692.html

1 · Reply

splendor Jul. 21 at 8:55 AM

$SNGX 3 key indicators pointing toward a potential CEPI funding announcement: Silence on Form 4 (No Insider Buys): Zero open-market buying from management. Under SEC regulations, insiders are under a legal blackout period during advanced grant negotiations to avoid material non-public information (MNPI) violations. Institutional Accumulation: MJL Manager group accumulated nearly 10% (983k shares) in late June. High-risk, asymmetrical bets of this size right after the CEPI application deadline suggest strong institutional conviction. Quiet Absorption Pattern: Premarket volume spikes combined with patient bid-side depth during regular hours. Big hands are quietly absorbing selling pressure without triggering price spikes. The setup looks tight. Waiting on the 8-K / PR

3 · Reply

splendor Jul. 20 at 4:27 PM

$SNGX 45%pr this week And 55% next week Cepi fund .

2 · Reply

Peterwiz Jul. 19 at 7:06 PM

$SNGX I hope it's not clot shot MRNA that screwed up a lot of my friends

1 · Reply

GreedyGopher Jul. 18 at 6:49 PM

$SNGX YES!!!!! after the next 1 for 15 reverse split, yes you will see $5, for a few days, until they annonunce a massive offering..... wash , rinse, repeat........schaber takes his 6 or figure bonus........never brought anything to market and never will

0 · Reply

Jvin1030 Jul. 18 at 5:47 AM

$SNGX can we see at least $5?

1 · Reply

Twoinfinity Jul. 17 at 10:55 PM

$SNGX there is always next week! Waiting for a positive PR!

0 · Reply

deme555 Jul. 16 at 3:00 PM

$SNGX how do you think guys, when the news will release?

3 · Reply

Market Cap	5.54M
Revenue (ttm)	0.00
Net Income (ttm)	-11.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	151,955
Avg Vol	8,681,404
Day's Range	N/A - N/A
Shares Out	14.82M
Stochastic %K	61%
Beta	1.92
Analysts	Strong Buy
Price Target	$1.75